Start-Up Spotlight: GNS Healthcare Deploys Causal Algorithms To Drive Health Outcomes, Save Costs
Executive Summary
GNS Healthcare wants to be on the forefront of the digital revolution in health care by offering its artificial intelligence powers to pharmaceutical and health-insurer customers to help them find the drivers of health outcomes and save costs along the way. It has also teamed up with research and patient foundations to expedite the R&D process, predict best treatment options for patients and create efficiencies for clinical trials.
You may also be interested in...
ACC Results Recap Part III: RADIANCE-HTM SOLO Results Support ReCor’s Renal Denervation System
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the third of three Results Recaps covering trial data presented at the American College of Cardiology Scientific Sessions in New Orleans, March 16-18, including the final results of the MOMENTUM 3 trial of Abbott’s HeartMate 3 left-ventricular assist device and six-month results from the RADIANCE-HTN SOLO trial of ReCor’s Paradise renal denervation system, and more. Check out Part I and Part II of our ACC Results Recap.
Market Intel: Digital Tech At The Heart Of Cardiology Innovation
Digital health technologies from smartphone applications, wearables, digital weight scales and telehealth are rapidly changing the landscape of cardiac care, offering new tools for engaging cardiology patients and enhancing cardiologists' workflows. There is a lot of hype, but also some real promise. Here's a look at what's happening and some expert insights on the benefits and challenges these new innovations represent, as well as market projections. Digital health was a major topic of discussion by cardiologists and entrepreneurs during this year's Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. This is the second in a series of articles on the future of cardiovascular technology, spotlighting discussion and presentations from TCT.
Roche Wins FDA Breakthrough Device Designation For Alzheimer’s Test
Roche announced on 11 April it received FDA breakthrough device designation for a blood test used for early detection of Alzheimer’s disease.